Project Grant R01DK140717
Award Date
8/10/24
Completion Date
6/30/28
Dollars Obligated
$756K
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) totals $167,768 and aims to evaluate whether beta-lactam antibiotics increase the risk of acute kidney injury (AKI) in patients receiving immune checkpoint inhibitor (ICI) cancer treatments, compared to fluoroquinolone antibiotics. The award will support a target trial emulation study to assess this...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $124,134 to Yale University to conduct research investigating the mechanisms underlying immune-related adverse events (IRAEs), specifically immune checkpoint inhibitor (ICI)-induced colitis, and to evaluate targeted therapies for mitigating colitis. The research aims to define the key T cell subsets and trafficking mechanisms driving colon inflammation in ICI-colitis, as well as to...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $796,293 to support research on the pathobiology of autoimmune-mediated diffuse podocytopathy. The grant aims to establish pathogenic autoimmunity in anti-nephrin mediated podocytopathy and identify direct downstream pathomechanistic effects of nephrin autoantibodies on podocyte...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $725,420 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop an optimized allysine-targeted positron emission tomography (PET) probe and validate it in animal models and human renal biopsy samples. The goal is to establish a non-invasive...
This $674,996 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sanford Burnham Prebys Medical Discovery Institute (SBP) to determine if targeting the PSGL-1 checkpoint inhibitor can promote the development and/or maintenance of CD8+ T cells essential for anti-tumor responses to PD-1 immune checkpoint blockade (ICB) therapy. The key objectives are to evaluate if PSGL-1 blockade can generate or sustain tumor-specific...
This $754,511 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to identify host genetic factors that influence the response to immune checkpoint inhibitor (ICI) cancer treatments. The principal investigator is using a mouse experimental platform to map quantitative trait loci (QTLs) associated with anti-tumor response to anti-PD1 immunotherapy, with a focus on defining the genetic mechanisms behind epistatic interactions...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $684,367 to the Baylor College of Medicine to conduct research aimed at identifying new predictors of response to immune checkpoint inhibitor (ICI) therapy in patients with non-small cell lung cancer (NSCLC). The key objectives are to: 1) Identify intratumoral microbiome profiles predictive of ICI response using whole-metagenome sequencing; 2) Characterize spatial immune...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $215,985 to The Leland Stanford Junior University to investigate the use of blood and urine exosomes as early biomarkers for predicting response to combination immune checkpoint inhibitor therapy (nivolumab plus ipilimumab) in patients with metastatic renal cell carcinoma (RCC). The research aims to 1) define an exosome signature of response by identifying exosomal...
The federal Project Grant award, valued at $312,892.00 and provided by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), supports research at Duke University to investigate the role of Type 3 innate lymphoid cells (ILC3s) in regulating the melanoma tumor microenvironment. The goal is to better understand how ILC3s modulate adaptive immune responses and create immunosuppressive conditions that may contribute to the failure of immune checkpoint inhibitor...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,181,683 to the Dana-Farber Cancer Institute in Boston, MA to conduct research aimed at enhancing immune checkpoint blockade responsiveness and tertiary lymphoid structure formation through CD4+TFHx13 CAR-T cells to achieve cures for clear cell renal cell carcinoma (CCRCC). The research will involve experimental design and computational analysis of...